Properties (54)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
company
|
| gptkbp:acquisition |
Acquired_by_BioTech_Corp_in_2015
|
| gptkbp:annualVisitors |
$5 million
|
| gptkbp:awards |
Best Biotech Startup 2010
|
| gptkbp:clinicalTrials |
Phase 3 trials
Phase 1 trials Phase 2 trials |
| gptkbp:collaborations |
gptkb:National_Institutes_of_Health
|
| gptkbp:communityInvolvement |
educational programs
local health initiatives |
| gptkbp:environmentalImpact |
sustainable practices
|
| gptkbp:financials |
non-profit organizations
|
| gptkbp:focusArea |
clinical trials
cancer research genetic therapies |
| gptkbp:foundedIn |
2002
|
| gptkbp:founder |
gptkb:Dr._John_Saxon
|
| gptkbp:headquarters |
gptkb:San_Diego,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
Saxon Sciences
|
| gptkbp:industry |
biotechnology
|
| gptkbp:investmentFocus |
Angel Investors
Venture_Capital_Firms |
| gptkbp:keyPeople |
gptkb:Dr._Jane_Doe
|
| gptkbp:market |
gptkb:Asia
gptkb:North_America Europe global |
| gptkbp:mission |
to innovate in biopharmaceuticals
|
| gptkbp:numberOfEmployees |
50-100
|
| gptkbp:parentCompany |
gptkb:Saxon_Group
|
| gptkbp:partnerships |
gptkb:University_of_California
|
| gptkbp:patentCitation |
10+ patents in biotechnology
|
| gptkbp:products |
biopharmaceuticals
|
| gptkbp:regulatoryCompliance |
FDA_approved
EMA_approved |
| gptkbp:research |
$20 million
|
| gptkbp:researchAreas |
immunotherapy
gene editing |
| gptkbp:researchInterest |
Research institutions
Pharmaceutical companies |
| gptkbp:services |
research and development
|
| gptkbp:socialResponsibility |
environmental sustainability programs
healthcare_access_initiatives |
| gptkbp:subsidiary |
gptkb:Saxon_Therapeutics
Saxon Diagnostics |
| gptkbp:technology |
data analytics
biotechnology platforms artificial intelligence in drug discovery |
| gptkbp:values |
gptkb:collaboration
innovation integrity excellence |
| gptkbp:vision |
to improve patient outcomes
|
| gptkbp:website |
www.saxon-sciences.com
|